AI has the potential to transform clinical research. In this webinar, Charles Fisher, Founder and CEO of Unlearn.AI, will provide an overview of artificial intelligence, and its innovative uses in clinical research. He will define machine learning (ML) and introduce how proprietary ML models can generate Digital Twins, or virtual patients, in external control arms of clinical trials. Incorporating Digital Twins into clinical trials can increase statistical power, accelerate trial timelines, and enable patient level insights, elevating clinical decision making and guiding future trial design. In this webinar, you will learn about:

• What AI is, and its role in clinical research
• How novel Machine Learning approaches are used to create Digital Twins
• The benefits and considerations of using Digital Twins in clinical trials

Clinical trials are critical for developing new treatments, but face chronic challenges, such as optimal trial design, enrollment, costs, timeline delays, and high failure rates. The gold standard of trial design is randomization, but it is not always ethical or feasible to set up a trial where the control group receives a standard of care or a placebo. Leveraging historical data sets and novel machine learning methods, Digital Twins, or statistically indistinguishable virtual placebo patients, can be generated to match actual patients in clinical studies. Adding external control arms populated with Digital Twins, called Intelligent Control Arms, can streamline clinical trials, increase power, and decrease enrollment, without adding regulatory risk. The FDA has expressed support for innovation in trial design and alternative forms of evidence - Digital Twins are the next frontier for modern trials.